…
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
BioLife Solutions develops and sells biopreservation media, cold-chain shipping systems and related storage solutions for cells, tissues and biologics used in cell and gene therapies, regenerative medicine and life-science research. Long-term growth may be supported by expanding advanced-therapy manufacturing, recurring consumables demand and geographic distribution, making the company a play on biomanufacturing supply chains and recurring revenue exposure.
Material risks include customer concentration, strong competition from larger life-science suppliers, reliance on continued commercial adoption of advanced therapies, regulatory scrutiny and supply-chain or manufacturing disruptions that could pressure revenue or margins.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -12.08M | -11.43M | -18.47M | -144.83M | -28.69M |
| Net income | -12.13M | -20.18M | -66.43M | -139.81M | -8.38M |
| Selling general administrative | 45.52M | 40.54M | 43.26M | 47.67M | 34.10M |
| Selling and marketing expenses | 9.85M | 9.61M | 12.71M | 21.57M | 14.00M |
| Gross profit | 62.12M | 53.67M | 46.75M | 53.82M | 37.75M |
| Reconciled depreciation | 4.69M | 8.66M | 13.09M | 16.47M | 8.20M |
| Ebit | - | -7.13M | -57.53M | -39.91M | -30.37M |
| Ebitda | -9.38M | 1.53M | -45.24M | -29.51M | -23.98M |
| Depreciation and amortization | - | 8.66M | 12.29M | 10.40M | 6.38M |
| Operating income | -12.13M | -7.13M | -23.44M | -39.91M | -30.37M |
| Other operating expenses | 108.34M | 89.38M | 99.30M | 201.67M | 149.52M |
| Interest expense | 2.71M | 0.72M | 1.81M | 0.69M | -0.43M |
| Tax provision | 0.05M | -0.04M | 0.13M | -5.02M | -20.31M |
| Net interest income | 2.71M | -0.72M | -1.74M | -0.69M | -0.43M |
| Income tax expense | 0.05M | -0.04M | 0.02M | -5.02M | -20.31M |
| Total revenue | 96.21M | 82.25M | 75.86M | 161.76M | 119.16M |
| Total operating expenses | 74.25M | 60.80M | 117.58M | 93.73M | 68.11M |
| Cost of revenue | 34.10M | 28.58M | 96.52M | 107.94M | 81.41M |
| Total other income expense net | 0.05M | -4.30M | 4.97M | -104.92M | 1.68M |
| Net income from continuing ops | -12.13M | -11.39M | -102.23M | -139.81M | -8.38M |
| Net income applicable to common shares | - | - | - | -139.81M | -8.38M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 405.88M | 399.49M | 412.71M | 450.23M | 552.60M |
| Intangible assets | 4.26M | 9.56M | 21.15M | 32.09M | 152.15M |
| Other current assets | -6.86M | 6.00M | 6.76M | 74.39M | 97.51M |
| Total liab | 34.00M | 50.58M | 75.05M | 86.04M | 71.85M |
| Total stockholder equity | 371.89M | 348.91M | 337.66M | -246.91M | 480.75M |
| Other current liab | 14.25M | 12.35M | 24.57M | 23.84M | 20.44M |
| Common stock | 0.05M | 0.05M | 0.04M | 0.04M | 0.04M |
| Capital stock | 0.05M | 0.05M | 0.04M | 0.04M | 0.04M |
| Retained earnings | -339.70M | -335.10M | -313.34M | -246.91M | -105.02M |
| Other liab | - | - | - | 2.58M | 31.88M |
| Good will | 208.59M | 212.30M | 224.74M | 224.74M | 224.74M |
| Other assets | - | - | - | 386.16M | 426.75M |
| Cash | 33.04M | 95.39M | 35.44M | 19.44M | 69.87M |
| Total current liabilities | 22.98M | 32.73M | 42.18M | 44.58M | 39.97M |
| Current deferred revenue | - | 0.10M | 0.66M | 0.55M | 0.81M |
| Net debt | -15.14M | -65.21M | 7.25M | 24.27M | -42.99M |
| Short term debt | 7.24M | 12.45M | 10.01M | 4.83M | 3.77M |
| Short long term debt | 5.00M | 10.94M | 6.83M | 1.81M | 0.86M |
| Short long term debt total | 17.90M | 30.17M | 42.69M | 43.71M | 26.88M |
| Other stockholder equity | 711.40M | 683.94M | 651.30M | 0.64M | 586.01M |
| Property plant equipment | - | - | - | - | 46.61M |
| Total current assets | 120.18M | 148.76M | 120.60M | 138.45M | 125.86M |
| Long term investments | 31.25M | 5.62M | 5.62M | 6.40M | 4.37M |
| Net tangible assets | - | - | - | 364.19M | 480.75M |
| Short term investments | 55.89M | 9.20M | 16.29M | 43.26M | - |
| Net receivables | 7.95M | 9.17M | 18.66M | 33.94M | 23.22M |
| Long term debt | - | 5.00M | 18.31M | 23.79M | 6.35M |
| Inventory | 30.16M | 29.01M | 43.46M | 34.90M | 28.34M |
| Accounts payable | 1.49M | 3.57M | 6.94M | 15.37M | 14.95M |
| Accumulated other comprehensive income | 0.13M | 0.02M | -0.34M | -0.68M | -0.28M |
| Non currrent assets other | 41.61M | 6.48M | 0.27M | 9.35M | 9.81M |
| Non current assets total | 285.71M | 250.73M | 292.11M | 311.78M | 426.75M |
| Capital lease obligations | 12.90M | 14.23M | 17.55M | 18.11M | 19.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -74.47M | 58.30M | -1.01M | -58.12M | -12.64M |
| Change to liabilities | - | - | - | 0.00M | 2.02M |
| Total cashflows from investing activities | -71.54M | 58.30M | - | -58.12M | -12.64M |
| Net borrowings | -10.00M | -6.61M | - | - | -2.89M |
| Total cash from financing activities | -10.92M | -6.78M | 10.59M | 16.32M | -2.78M |
| Change to operating activities | - | - | - | 1.99M | 4.47M |
| Net income | -4.59M | -20.18M | -66.43M | -139.81M | -7.63M |
| Change in cash | -62.35M | 59.95M | 15.96M | -50.40M | -20.59M |
| Begin period cash flow | 95.39M | 35.44M | 19.47M | 69.87M | 90.46M |
| End period cash flow | 33.04M | 95.39M | 35.44M | 19.47M | 69.87M |
| Total cash from operating activities | 20.11M | 8.43M | -12.50M | -8.49M | -4.84M |
| Issuance of capital stock | 0.00M | 0.00M | 10.24M | 0.00M | -0.13M |
| Depreciation | 4.69M | 5.49M | 12.29M | 16.47M | 12.87M |
| Other cashflows from investing activities | -71.54M | -2.37M | - | -58.12M | -12.64M |
| Change to inventory | -1.27M | 0.78M | -8.55M | -6.56M | 0.11M |
| Change to account receivables | 0.26M | -2.90M | 15.35M | -10.75M | -10.13M |
| Other cashflows from financing activities | -0.94M | -0.38M | 0.84M | -1.52M | 0.12M |
| Change to netincome | - | - | - | 114.79M | -8.97M |
| Capital expenditures | 9.48M | 3.23M | 6.38M | 10.38M | 8.38M |
| Change in working capital | -8.91M | 0.23M | 1.47M | -14.90M | -3.53M |
| Stock based compensation | 22.99M | 30.92M | 31.67M | 25.33M | 13.96M |
| Other non cash items | 29.02M | -7.96M | 8.56M | 109.65M | -0.36M |
| Free cash flow | 10.64M | 5.20M | -18.88M | -18.87M | -13.22M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ISRG Intuitive Surgical Inc |
-8.32 2.04% |
398.92 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-2.84 1.45% |
192.96 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-1.82 1.88% |
95.04 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
0.10 0.05% |
212.78 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
3303 Monte Villa Parkway, Bothell, WA, United States, 98021
425 402 1400
155
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael P. Rice | Chairman & CEO | 1963 |
| Mr. Roderick de Greef | Pres & COO | 1960 |
| Mr. Troy Wichterman | Chief Financial Officer | 1985 |
| Dr. Aby J. Mathew | Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer | 1972 |
| Mr. Marcus Schulz | Chief Revenue Officer | 1979 |
| Mr. Todd Berard | Chief Marketing Officer | 1969 |
| Ms. Sarah Aebersold J.D. | VP of Global HR | 1976 |
| Ms. Karen Foster | Chief Quality Officer | 1960 |
| Mr. Roderick de Greef | CEO & Chairman | 1960 |
| Ms. Karen Foster | Chief Quality & Operations Officer | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.